US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

(OP:ONNVF)

0.2327 -0.0399 (-14.64%)
Delayed Quote Updated: 3:27 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ONNVF

< Previous 1 2 3 4 Next >
News headline image
Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Private Placement
Via ACCESS Newswire
News headline image
Onco-Innovations Appoints Dr. Dennis Hall to Scientific & Clinical Advisory Board
Via ACCESS Newswire
News headline image
Onco-Innovations Signs Agreement with Redwood AI to Advance Discovery and Evaluation of Its PNKP Inhibitor Technology
Via ACCESS Newswire
News headline image
Onco-Innovations Strengthens Clinical Leadership with Appointment of Dr. Islam Mohamed as Advisory Board Chair
Via ACCESS Newswire
News headline image
Onco-Innovations Enters Agreement with Nucro-Technics for IND-Enabling Studies, Taking a Key Step Toward Human Trials
Via ACCESS Newswire
News headline image
Onco-Innovations CEO Highlights Strategic Milestones and R&D Progress in Special Investors' Conference Call
Via ACCESS Newswire
News headline image
Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology Consortium
Via ACCESS Newswire
News headline image
Onco-Innovations' CEO to Host Special Investors' Conference Call on Wednesday, July 2, 2025
Via ACCESS Newswire
News headline image
Inka Health Co-Founders Publish New Study Advancing Real-World Applicability of Lung Cancer Clinical Trial Outcomes
Via ACCESS Newswire
News headline image
Onco-Innovations Engages the University of Alberta and Cross Cancer Institute to Expand PNKP Inhibitor Research into Hard-to-Treat Cancers
Via ACCESS Newswire
News headline image
Onco-Innovations' Inka Health to Launch Global AI-Oncology Consortium to Advance Predictive Cancer Research
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Start of Manufacturing of Preclinical Testing Material for Its PNKP Inhibitor Technology by Dalton Pharma
Via ACCESS Newswire
News headline image
Onco-Innovations Extends Marketing Program
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Appointment of Professor Steven Jones as Senior Scientific Advisor, Strengthening Technical Acumen in AI-Powered Precision Oncology
Via ACCESS Newswire
News headline image
Onco-Innovations Celebrates Listing of Common Shares on Cboe Canada
Via ACCESS Newswire
News headline image
Onco-Innovations' Inka Health Signs New Analytical Work with AstraZeneca Canada to Advance Real-World Evidence in Regulatory Science
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Private Placement
Via ACCESS Newswire
News headline image
Onco-Innovations’ Inka Health Publishes Roche-Sponsored Study Advancing Real-World Oncology Research
Via ACCESS Newswire
News headline image
Onco-Innovations' Inka Health Completes Analytical Work for AstraZeneca Canada, Advancing Pharmaceutical Analytics and Leading to Key Studies at ISPOR 2025
Via ACCESS Newswire
News headline image
Onco-Innovations' PKNP Technology Used with Radiation Therapy Shown in Study to Demonstrate Low Toxicity and High Safety Profile
Via ACCESS Newswire
News headline image
Onco-Innovations Extends Marketing Program
Via ACCESS Newswire
News headline image
Onco-Innovations Provides Update on Use of Proceeds
Via ACCESS Newswire
< Previous 1 2 3 4 Next >